Antibacterial resistances in uncomplicated urinary tract infections in women: ECO·SENS II data from primary health care in Austria

BMC Infectious Diseases

Kathryn Hoffmann¹  Wolfgang Spiegel¹  Waltraud Fink¹  Sonja Zehetmayer²  Gernot Wagner¹  Gustav Kamenski¹ 

[1] Department of General Practice, Centre for Public Health, Medical University of Vienna, Währingerstrasse 13a/III, 1090, Vienna, Austria;Department of Medical Statistics, Medical University Vienna, Spitalgasse 23, 1090, Vienna, Austria

关键词: Antibiotic resistance;    Austria;    Primary health care;    Uncomplicated urinary tract infection;   

Others  :  1159679
DOI  :  10.1186/1471-2334-12-222

 received in 2012-01-31, accepted in 2012-09-07,  发布年份 2012

【 摘 要 】

Background

Uncomplicated urinary tract infections (UTI) are a frequent reason for consultation of women in primary health care. To avoid therapy failure and development of resistances, the choice of an antibiotic should be based on the knowledge of recent local resistance data but these data are scarce for the Austrian primary health care sector. Within the context of the ECO·SENS II study it was the aim to obtain appropriate and relevant local resistance data and describe the changes in the resistance pattern in comparison to the ECO·SENS study.

Methods

23 GPs from different parts of Austria participated in the study between July 2007 and November 2008. According to the defined inclusion- and exclusion criteria female patients with symptoms of an uncomplicated UTI were included and a midstream urine sample was collected. In case of significant bacteriuria susceptibility testing of E. coli against 14 antibiotics was performed. Descriptive statistical methods were used.

Results

In 313 patients included in the study, a total of 147 E. coli isolates (47%) were detected and tested. The resistance rates were in %: Mecillinam (0.0), nitrofurantoin (0.7), fosfomycin trometamol (0.7), gentamycin (1.4), cefotaxime (2.7), ceftazidime (2.7), Cephadroxil (4.1) and ciprofloxacin (4.1). Higher resistance rates were found in amoxicillin/clavulanic acid (8.9), nalidixic acid (9.6), trimethoprim/sulphamethoxazole (14.4), trimethoprim (15.8), sulphamethoxazole (21.2) and ampicillin (28.8). Additionally, the comparison of these results with the results of the ECO·SENS study demonstrated an increase in resistance rates of ampicillin, amoxicillin/clavulanic acid, nalidixic acid and ciprofloxacin.

Conclusions

The resistance data for E. coli in uncomplicated UTIs in women gained by this study are the most recent data for this disease in Austria at the moment. The increased resistance rates of amoxicillin/clavulanic acid, ciprofloxacin and nalidixic acid should be respected when choosing an appropriate antibiotic for uncomplicated UTIs. The use of ampicillin, sulphamethoxazole, trimethoprim and trimethoprim/sulphametoxazole in uncomplicated UTIs in women should be questioned at all. The findings of this study should result in a regular surveillance system of resistances emerging in the ambulatory sector designed after the model of the EARS-Net.

【 授权许可】

   
2012 Kamenski et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 1.

【 参考文献 】

• [1]Little P, Merriman R, Turner S, Rumsby K, Warner G, Lowes JA, Smith H, Hawke C, Leydon G, Mullee M, et al.: Presentation, pattern, and natural course of severe symptoms, and role of antibiotics and antibiotic resistance among patients presenting with suspected uncomplicated urinary tract infection in primary care: observational study. BMJ 2010, 340:b5633.
• [2]Fink W, Haidinger G: Prevalence of health problems in a family practice observed over 10 years. Z Allg Med 2007, 83:102-108.
• [3]Alos JI: Epidemiology and etiology of urinary tract infections in the community. Antimicrobial susceptibility of the main pathogens and clinical significance of resistance. Enferm Infecc Microbiol Clin 2005, 23(Suppl 4):3-8.
• [4]Giesen LG, Cousins G, Dimitrov BD, van de Laar FA, Fahey T: Predicting acute uncomplicated urinary tract infection in women: a systematic review of the diagnostic accuracy of symptoms and signs. BMC Fam Pract 2010, 11:78. BioMed Central Full Text
• [5]Foxman B: Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Dis Mon 2003, 49(2):53-70.
• [6]Foxman B, Barlow R, D'Arcy H, Gillespie B, Sobel JD: Urinary tract infection: self-reported incidence and associated costs. Ann Epidemiol 2000, 10(8):509-515.
• [7]Nicolle LE: Empirical treatment of acute cystitis in women. Int J Antimicrob Agents 2003, 22(1):1-6.
• [8]Graninger W: Pivmecillinam–therapy of choice for lower urinary tract infection. Int J Antimicrob Agents 2003, 22(Suppl 2):73-78.
• [9]Ferry SA, Holm SE, Stenlund H, Lundholm R, Monsen TJ: The natural course of uncomplicated lower urinary tract infection in women illustrated by a randomized placebo controlled study. Scand J Infect Dis 2004, 36(4):296-301.
• [10]Leitlinie Brennen beim Wasserlassenhttp://www.evidence.de/Leitlinien/leitlinien-intern/HWI_Start/HWIText/hwitext.html webcite
• [11]Allerberger F, Frank A, Gareis R: Antibiotic stewardship through the EU project "ABS International". Wien Klin Wochenschr 2008, 120(9–10):256-263.
• [12]Hoffmann K, Wagner G, Apfalter P, Maier M: Antibiotic resistance in primary care in Austria - a systematic review of scientific and grey literature. BMC Infect Dis 2011, 11:330. BioMed Central Full Text
• [13]Butler CC, Hillier S, Roberts Z, Dunstan F, Howard A, Palmer S: Antibiotic-resistant infections in primary care are symptomatic for longer and increase workload: outcomes for patients with E. coli UTIs. Br J Gen Pract 2006, 56(530):686-692.
• [14]Apfalter P, Allenberger F, Fluch G, Oegger G: Resistenzbericht Österreich. AURES 2009. Antibiotikaresistenz und Verbrauch antimikrobieller Substanzen in Österreich. Vienna: Bundesministerium für Gesundheit; 2010.
• [15]Mittermayer H, Metz-Gercek S, Allerberger F: Resistenzbericht Österreich. AURES 2008. Antibiotikaresistenz und Verbrauch antimikrobieller Substanzen in Österreich. Wien: Bundesministerium für Gesundheit; 2009.
• [16]Schito GC, Naber KG, Botto H, Palou J, Mazzei T, Gualco L, Marchese A: The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections. Int J Antimicrob Agents 2009, 34(5):407-413.
• [17]Kahlmeter G: An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECO. SENS Project. J Antimicrob Chemother 2003, 51(1):69-76.
• [18]Magee JT, Pritchard EL, Fitzgerald KA, Dunstan FD, Howard AJ: Antibiotic prescribing and antibiotic resistance in community practice: retrospective study, 1996-8. BMJ 1999, 319(7219):1239-1240.
• [19]Bent S, Nallamothu BK, Simel DL, Fihn SD, Saint S: Does this woman have an acute uncomplicated urinary tract infection? JAMA 2002, 287(20):2701-2710.
• [20]Rubin RH, Shapiro ED, Andriole VT, Davis RJ, Stamm WE: Evaluation of new anti-infective drugs for the treatment of urinary tract infection. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis 1992, 15(Suppl 1):S216-S227.
• [21]Swedish Reference Group for Antibiotics and its Subcommitteee on Methodologyhttp://www.srga.org webcite
• [22]Wagenlehner FM, Hoyme U, Kaase M, Funfstuck R, Naber KG, Schmiemann G: Uncomplicated urinary tract infections. Dtsch Arztebl Int 2011, 108(24):415-423.
• [23]Allerberger F, Apfalter P, Burgmann H, Gareis R, Janata O, Krause R, Lechner A, Stanek G, Wechsler-Fördös A: ABS im niedergelassenen Bereich; Diagnose und Therapie von Infektionskrankheiten im niedergelassenen Bereich und in Spitalsambulanzen. Vienna: ABSGROUP GmbH; 2011.
• [24]Arpin C, Quentin C, Grobost F, Cambau E, Robert J, Dubois V, Coulange L, Andre C: Nationwide survey of extended-spectrum {beta}-lactamase-producing Enterobacteriaceae in the French community setting. J Antimicrob Chemother 2009, 63(6):1205-1214.
• [25]Metz-Gercek S, Maieron A, Strauss R, Wieninger P, Apfalter P, Mittermayer H: Ten years of antibiotic consumption in ambulatory care: trends in prescribing practice and antibiotic resistance in Austria. BMC Infect Dis 2009, 9:61. BioMed Central Full Text
• [26]Goossens H, Ferech M, Vander Stichele R, Elseviers M: Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet 2005, 365(9459):579-587.
• [27]Masterton R: The importance and future of antimicrobial surveillance studies. Clin Infect Dis 2008, 47(Suppl 1):S21-S31.
• [28]EARS-Nethttp://www.ecdc.europa.eu/en/activities/surveillance/EARS-Net/Pages/index.aspx webcite
• [29]Wagenlehner FM, Vahlensieck W, Bauer HW, Weidner W, Naber KG, Piechota HJ: Primary and secondary prevention of urinary tract infections. Urologe A 2011, 50(10):1248. 1250-1242, 1254-1246